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DEVELOPMENT OF LOW ENERGY ACCELERATOR-BASED
PRODUCTION OF MEDICAL ISOTOPES
N. Ratcliffe∗, R. Barlow, R. Cywinski, University of Huddersfield, Huddersfield, HD1 3BH, UK
P. Beasley, Siemens AG, Oxford, OX1 2EP, UK
Abstract
Here we present methods for production of new and ex-
isting isotopes for SPECT (Single Photon Emission Com-
puted Tomography) and PET (Positron Emission Tomog-
raphy) imaging using accelerator-based systems. Such iso-
topes are already widely used in medical diagnostics and
research, and there is constant development of new drugs
and isotopes. However the main production method for
99mTc, is currently in research reactors and is at risk due
to scheduled and unscheduled shut downs. Therefore, a
low cost an alternative accelerator-based system could pro-
vide many advantages. Various compact low energy proton
machines are being proposed to enable cheap and acces-
sible production: here we present a discussion of potential
new SPECT isotopes and simulations of suitable targets for
their manufacture.
INTRODUCTION
Currently the production of medical tracer isotopes for
use in imaging techniques such as SPECT (Single Pho-
ton Emission Computed Tomography) and PET (Positron
Emission Tomography) [1] relies principally upon an age-
ing fleet of nuclear reactors. For example the most com-
mon medical isotope 99mTc, used in over 80% of all radio-
pharmaceutical procedures, is currently produced, via its
generator 99Mo, by nuclear research reactors such as NRU-
Canada and HFR-The Netherlands, which together produce
over 60% of the worlds 99Mo/99mTc supply. Both of these
reactors are old (>50yrs) and close to decommissioning,
and while several projects are looking at other production
routes for this isotope, as yet there is no real replacement in
place [2, 3]. As these reactors near their decommissioning,
currently set at 2014-2016, there is considerable concern
that we will soon be facing a similar situation to that of the
2010 isotope crisis, when both reactors were offline simul-
taneously resulting in a significant decrease in the supply of
99mTc and the postponing or cancelation of many vital ra-
dioisotope procedures [1–5]. Due to 99mTc monopolising
the medical isotope market little work was done develop-
ing other isotopes and many potential isotopes fell by the
wayside. The aim of this work is to resurrect some of these
isotopes as alternatives to 99mTc as we head into another
shortage in the hope of preventing another crisis. There are
several short lived SPECT and PET isotopes that have the
potential to take some of the workload from 99mTc.
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LOW ENERGY ISOTOPE PRODUCTION
We believe that the solution to this impending problem
could lie in accelerator-based production methods, of both
99mTc and possible replacement isotopes. A collaboration
with Siemens is focusing on the potential of a compact,
low energy proton device for the generation of radioiso-
topes [6]. Such a machine could provide many more lo-
calised isotope production centres and allow for the use
of isotopes with shorter halflives. A study of optimal tar-
get designs for such a system has been undertaken using
GEANT4 simulations of low energy (<10MeV) proton in-
duced reactions.
113M
INDIUM
113mIn is a metastable radioactive isotope that decays via
a 392 keV γ into stable 113In with a half life of 1.7hours [7].
In 1965 it was first proposed for use as an alternative med-
ical tracer isotope to 99mTc for SPECT imaging in sev-
eral applications such as brain and lung scanning. Tri-
als of this isotope showed it to give results comparable to
99mTc images [7]. 113mIn showed several advantages over
99mTc such in terms of chemical properties. A success-
ful generator production system for In was developed using
113Sn [7, 8].
Generator Production
There are several advantages of a longer lived genera-
tor system, such as the Sn/In system. The longer gap be-
tween parent half life and daughter half life makes it easier
to separate the two nuclei. It also increases the longevity of
the system for example the Sn/In(parent half life approx-
imately 118 days) system only needs replacing once ev-
ery 6 months where as the Mo/Tc(parent half life approx-
imately 3 days) system needs replacing weekly. However
due the plentiful and cheap supply of Tc at the time very
little serious work was carried forward with this isotope.
The simplicity of the generator production system and the
advantages available from such a system has prompted the
exploration of a low energy method of production for this
generator using the reaction:
113In(p,n)113Sn→ 113mIn→ 113In
Preliminary simulation results from the TALYS data li-
braries show that such a reaction at 10 MeV gives a produc-
tion cross section of 570mb. Further GEANT4 simulations
have been used to study target designs and feasibility of this
reaction using a<10MeV proton beam. In terms of daugh-
ter yield the most appropriate target thickness is that of just
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over the stopping distance, which from these simulations
is given to be approximately 0.5mm. The generator and
daughter activity for this reaction after a 30min irradiation
of the target can be seen in Fig. 1.
Figure 1: Activity of parent 113Sn and daughter 133mIn pro-
duced from the generator reaction.
The lifetime of a typical Sn/In generator system is 3-
6 months [9]. The activity for this time after irradiation
can be seen in Fig. 1. Even after this time this small sam-
ple generator is producing an activity of 0.9 mCi which
in comparison to a typical single dose of microcuries per
gram [10], shows the potential of a low energy accelerator
based system for the generator production of 113mIn.
Direct Production
Direct production of 113mIn appears to be less common
due to the short halflife of the isotope and the lack of lo-
cal facilities in which to produce it. However with the in-
troduction of our proposed system it should be possible to
make this a much more feasible production route. Both the
TENDL and EXFOR libraries can be seen to agree that a
cross section of just over 200mb can be obtained for the
following reaction:
113Cd(p,n)113mIn
for a proton beam between 9 and 10 MeV. The corre-
sponding activity of In for a 0.5mm thick target after a
30min irradiation can be seen in Fig. 2.
The activity obtained for direct production is signifi-
cantly larger than that of generator production. Such ac-
tivity should be enough to service the needs for a local fa-
cility as is the proposed purpose of a low energy isotope
production system.
87M
STRONTIUM
Strontium 87m is a metastable radioactive isotope that
decays via a 388keV γ into stable 87Sr with a half life of
2.8hours [11]. Several different strontium isotopes have
an application in nuclear medicine as due to the similar
Figure 2: Activity of 113In produced from the direct reac-
tion.
chemistry to calcium it is readily taken up in bone. There
are some isotopes such as 90Sr which are undesirable for
medial use as replace calcium in the bone and are toxic.
Others however such as 87mSr can be used in both diag-
nostic and therapeutic techniques for various skeletal dis-
eases [11–14].
Generator Production
87mSr is produced primarily using the 87Y/87mSr gener-
ator. Literature shows many different possible methods of
producing this generator. However these are all at higher
energies (>20 MeV). This work is focusing on low energy
techniques e.g. reactions such as
87Sr(p,n)87Y→ 87mSr→ 87Sr
According to the TALYS/EXFOR libraries this reac-
tion has a cross section of approximately 600mb at 10
MeV. Further study of target design were carried out using
GEANT4 to obtain a suitable target that provides a viable
yield for medical applications. The activity obtained from
a 0.9mm thick metal target can be seen in Fig. 3.
Activity of the generator route from our simulations is of
the order of curies whilst a diagnostic dose is of the order
of millicurie. However from previous studied such as [11]
it is apparent that this target is impractical and a compound
target such as SrCl2 would be more appropriate. This re-
duces the number of Sr nuclei within the target requiring a
thicker compound target to keep the activity sufficient for
the 2 week lifespan that is typical of this type of generator
system.
Direct Production
It is also proposed that direct production of 87mSr is pos-
sible through the reaction:
87Rb(p,n)87mSr
which according to the EXFOR libraries has a cross sec-
tion of approximately 200mb in the energy range<10MeV.
The TALYS libraries also gave a cross section of 240mb at
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Figure 3: Activity of 87mSr produced using the 87Y/87mSr
generator.
Figure 4: Activity of 87mSr produced using the direct reac-
tion.
10MeV from which the activity of 87mSr that is produced
after a 30min irradiation of a 0.5mm thick target can be
seen in Fig. 4.
Even with such a simple, crude design such a large ac-
tivity is obtained with this reaction. With more adjustment
a suitable target could be configured so as to optimise the
activity. An isotope with such a short half life is much more
likely to be produced using the direct reaction on demand
and so any effort to minimise the production time such as
short irradiation time, from these initial results this time
could be less than 30mins.
CONCLUSION
This work has shown a first test case of the feasibility
and practicality of using a low energy proton accelerator
system as a method of producing radioisotopes in quanti-
ties suitable for medical applications. This work will go on
to optimise the low energy production routes for these iso-
topes in the hopes of minimising the reduction of SPECT
isotopes in the predicated crisis. We will also go on to study
the potential of using this system to manufacture potential
isotopes to be introduced for both SPECT and PET.
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